Global Markets

The Boston cream of life sciences: All the winners from the BWB Awards

The BWB Awards celebrated the best in life sciences last night with comedian Paula Poundstone dishing out the honors. “What is biotechnology?” compere Paula Poundstone asked a packed room of biotech execs in Boston. “Does it have to do with teaching dogs to sniff for COVID?” The audience at the BWB Awards reassured her that it was slightly more extensive than that in a night where the biotech and life science communities came together to celebrate their successes over the…

CDMOs: ‘Invest in bio capacity now to meet surging demand over next 5 years’

With new targets coming from smaller biotech, there are huge opportunities for contract manufacturers that can invest today in anticipation of the demand tomorrow, says GlobalData. Ahead of his presentation at Connect to Frankfurt (opening September 28th) – a new digital platform accompanying CPHI Worldwide in Frankfurt, Germany – BioProcess Insider spoke with Quentin Horgan, associate director, Pharmaceutical Data & Analytics at analytics and consultancy firm GlobalData.   He looks ahead to what are likely to be the biggest selling…

Danaher merging Cytiva and Pall to create $7.5bn bioprocess juggernaut

Combining Cytiva and Pall will create the “broadest” and “deepest” bioprocess product portfolio in the industry, says Danaher Corporation. The decision to create ‘The Biotechnology Group’ by merging Danaher’s two bioprocess businesses was announced at the firm’s 2022 Investor & Analyst event last week. Introducing the combined entity, Danaher CEO Rainer Blair told stakeholders the decision represents the third phase in his company’s acquisitional strategy in the bioprocess space, having first acquired and “carved out” the two businesses – Pall…

MeiraGTx opens first commercial-scale gene therapy plant in Ireland

MeiraGTx has opened what it claims is the first commercial-scale gene therapy manufacturing site in Shannon, Ireland. Clinical stage gene therapy firm MeiraGTx Holdings has “unveiled” its 150,000 square-foot production facility in Shannon, Ireland with Micheál Martin, the Head of the Irish Government in attendance. “The plasmid facility has been operating actively since early this year and is now reaching a level of maturity to achieve full GMP standard and application for commercial licenses,” a spokesperson for the firm told…

Bluebird Skysona approval: ‘A resurgence for HSC gene therapy’

The US approval of bluebird bio’s Skysona (eli-cel) marks a resurgence for the wider hematopoietic stem cell (HSC) gene therapy sector, says AVROBIO. Following the endorsement by an Advisory Committee in June, the US Food and Drug Administration (FDA) granted approval of bluebird bio’s Skysona (elivaldogene autotemcel, or eli-cel) Friday for the treatment of active cerebral adrenoleukodystrophy (CALD). Skysona uses ex vivo transduction with a Lenti-D lentiviral vector (LVV) to add functional copies of the ABCD1 gene into a patient’s…

AbbVie: Manufacturing consistency will affect Humira biosimilar uptake

AbbVie says payors will look to consistent global supply as a key differentiator among the many Humira biosimilar makers poised to enter the US market. AbbVie’s autoimmune monoclonal antibody (mAb) Humira (adalimumab) is the bestselling drug of all time, clocking in over $193 billion for AbbVie (and previously Abbott) since its launch in 2003 to the end of 2021. Last year alone it pulled in $20.7 billion (though lost out to the industry’s top seller spot due to $36.9 billion…

BMS confident Breyanzi capacity issues will be resolved in 2023

Bristol Myers Squibb will apply the same strategy used to increase Abecma supply to increase capacity for Breyanzi as it pushes back projected timelines into next year. Bristol Myers Squibb (BMS) has with its chimeric antigen receptor (CAR) T-cell therapy Breyanzi (liso-cel) “a best-in-class profile,” Christopher Boerner, EVP & chief commercialization officer told stakeholders at the Morgan Stanley Global Healthcare Conference last week. Having been approved in February 2021 for Large B-cell Lymphoma, the therapy won second-line approval for relapsed…

Biden pledges $2bn to launch US biomanufacturing initiative

The US government will invest over $2 billion to launch its biomanufacturing initiative, which aims to expand manufacturing capacity in the country and ensure pandemic preparedness. The Executive Order was signed by President Biden on Monday and outlines the key goals of the biomanufacturing initiative. Overall, the Order looks to strengthen the country’s supply chain in the biopharma space and to reduce reliance on foreign manufacturing for the drug industry. Biden said it is the policy of his Administration to…

Rubius weighs up RI plant sale as part of pipeline restructure

Rubius Therapeutics will also cut 75% of its staff as it discontinues its solid tumor programs in favor of developing a next-generation red blood cell-based cell conjugation platform. Massachusetts-based Rubius announced yesterday it is scrapping clinical programs RTX-240 and RTX-224 for solid tumors and instead focusing on improving the efficacy of the tech platform they were based on. “Following careful review of recent technical progress in an alternative format for making Red Cell Therapeutics, we believe that this process has…

Novartis looks beyond mAbs with $270m manufacturing spending spree

Novartis is making a multi-year investment across three European manufacturing sites to support a growing early-stage pipeline of next-generation biologics. Pharma giant Novartis announced the investments this week, with facilities in Switzerland, Slovenia, and Austria set to see increased drug substance and drug product capabilities. Specifically, $110 million will be injected in clinical manufacturing and technical development capabilities at the firm’s Mengeš, Slovenia site, while $60 million will be used to add technical manufacturing capacity at the Schaftenau campus in…